A Randomised, Double-blind, Placebo-controlled, Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Intranasal RV568 in Healthy Volunteers
Latest Information Update: 04 Jul 2016
At a glance
- Drugs RV 568 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease; Seasonal allergic rhinitis
- Focus Adverse reactions
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
- 22 May 2013 Pharmacodynamic results (cohort 2) presented at the 109th International Conference of the American Thoracic Society.
- 22 May 2013 Pharmacodynamic results (cohort 1) presented at the 109th International Conference of the American Thoracic Society.